S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
Log in
NASDAQ:LEGN

Legend Biotech Stock Forecast, Price & News

$27.35
-1.51 (-5.23 %)
(As of 01/22/2021 04:40 PM ET)
Add
Compare
Today's Range
$27.25
Now: $27.35
$29.00
50-Day Range
$27.59
MA: $29.85
$32.40
52-Week Range
$24.64
Now: $27.35
$43.24
Volume668,108 shs
Average Volume355,143 shs
Market Capitalization$3.53 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

MarketRank

Overall MarketRank

1.25 out of 5 stars

Medical Sector

758th out of 1,922 stocks

Pharmaceutical Preparations Industry

383rd out of 769 stocks

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LEGN
CUSIPN/A
CIKN/A
Phone732-317-5050
Employees800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.39 million

Profitability

Net Income$-132,970,000.00
Net Margins-543.73%

Miscellaneous

Market Cap$3.53 billion
Next Earnings DateN/A
OptionableNot Optionable
$27.35
-1.51 (-5.23 %)
(As of 01/22/2021 04:40 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LEGN News and Ratings via Email

Sign-up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Legend Biotech (NASDAQ:LEGN) Frequently Asked Questions

Is Legend Biotech a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Legend Biotech stock.
View analyst ratings for Legend Biotech
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Legend Biotech?

Wall Street analysts have given Legend Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Legend Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Legend Biotech's CEO?

1,448 employees have rated Legend Biotech CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Legend Biotech's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) issued its earnings results on Sunday, November, 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.19. The business had revenue of $11.75 million for the quarter, compared to the consensus estimate of $12.80 million. Legend Biotech had a negative return on equity of 205.60% and a negative net margin of 543.73%.
View Legend Biotech's earnings history
.

What price target have analysts set for LEGN?

3 brokers have issued twelve-month target prices for Legend Biotech's stock. Their forecasts range from $47.00 to $55.00. On average, they anticipate Legend Biotech's share price to reach $50.67 in the next twelve months. This suggests a possible upside of 85.3% from the stock's current price.
View analysts' price targets for Legend Biotech
or view Wall Street analyst' top-rated stocks.

Who are some of Legend Biotech's key competitors?

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

Who are Legend Biotech's key executives?

Legend Biotech's management team includes the following people:
  • Dr. Ying Huang, CEO & CFO (Age 47)
  • Dr. Frank Fan M.D., Ph.D., Co-Founder & Chief Scientific Officer
  • Jessie Yeung, Head of Corp. Fin. & Investor Relations
  • Deborah Wong, Exec. Director of Strategic Marketing & Corp. Communications
  • Dr. Meeta Chatterjee Ph.D., Sr. VP of Global Bus. Devel.
  • Ms. Liz Gosen, Sr. VP of Global Technical Operations
  • Surabhi Verma, Mang. of Investor Relations & Corp. Communications

When did Legend Biotech IPO?

(LEGN) raised $350 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO.

What is Legend Biotech's stock symbol?

Legend Biotech trades on the NASDAQ under the ticker symbol "LEGN."

When did Legend Biotech's lock-up period expire?

Legend Biotech's lock-up period expired on Wednesday, December 2nd. Legend Biotech had issued 18,425,000 shares in its public offering on June 5th. The total size of the offering was $423,775,000 based on an initial share price of $23.00. Since the expiration of Legend Biotech's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

How do I buy shares of Legend Biotech?

Shares of LEGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Legend Biotech's stock price today?

One share of LEGN stock can currently be purchased for approximately $27.35.

How big of a company is Legend Biotech?

Legend Biotech has a market capitalization of $3.53 billion and generates $64.39 million in revenue each year. Legend Biotech employs 800 workers across the globe.

What is Legend Biotech's official website?

The official website for Legend Biotech is www.legendbiotech.com.

How can I contact Legend Biotech?

Legend Biotech's mailing address is 2101 COTTONTAIL LANE, SOMERSET NJ, 08873. The company can be reached via phone at 732-317-5050 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.